Patents Examined by Barry A Chestnut
  • System and method for characterizing protein dimerization
    Patent number: 11525823
    Abstract: Systems and methods to characterize dimerization interfaces at the subdomain level of a protein are provided. An exemplary method includes digesting a protein dimer sample into subdomains, labeling the digested protein sample, isolating labeled dimeric and monomeric subdomain fragments, and peptide mapping the labeled sample to determine where the dimer fragments are labeled and where the dimer fragments are not labeled. Regions that show decreased labeling extents in the dimer fraction than that in the monomer fraction are likely involved or in close proximity to the dimerization interface.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 13, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Yuetian Yan
  • Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
    Patent number: 11517618
    Abstract: Methods of inducing an immune response against human immunodeficiency virus (HIV) are described. In particular, methods of inducing an immune response against HIV by co-locally administering an immunogenically effective amount of an isolated HIV envelope (Env) polypeptide and an immunogenically effective amount of an adenovirus vector encoding an HIV antigen, e.g., Env antigen are described. The isolated HIV Env polypeptide and adenovirus vector can be administered in a single composition or in separate compositions, in which the composition or compositions do not contain an adjuvant.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 6, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Frank Wegmann, Gijs Hardenberg, Roland Christian Zahn
  • Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
    Patent number: 11510975
    Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating cancer.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: November 29, 2022
    Assignee: Replicate Bioscience, Inc.
    Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
  • Variant AAV capsids for intravitreal delivery
    Patent number: 11510950
    Abstract: Provided are variant adeno-associated virus (AAV) capsid proteins and recombinant AAV virions having one or more variant AAV capsid proteins. Also provided are compositions and methods for the use of the recombinant AAV virions, such as for the treatment or prophylaxis of a disease or disorder.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 29, 2022
    Assignee: ADVERUM BIOTECHNOLOGIES, INC.
    Inventors: Annahita Keravala, Diana Cepeda, Mehdi Gasmi
  • Whole avian-origin reverse genetic system and recombinant H5N2 subtype avian influenza virus, vaccine and uses thereof
    Patent number: 11512117
    Abstract: The present disclosure discloses a whole avian-origin reverse genetic system, a recombinant H5N2 subtype avian influenza virus, a vaccine containing the virus, and a preparation method and application thereof. The genome of the recombinant virus is comprised of a modified HA gene derived from a highly pathogenic H5N6 subtype avian influenza virus strain, as well as PB2, PB1, PA, NP, NA, M and NS genes derived from H5N2 subtype avian influenza D7 virus strain. The recombinant virus is a recombinant H5N2 avian influenza virus rescued from the D7 virus strain as a backbone, which is an avirulent virus strain with the original immunogenicity, and can maintain a high virus titer during the chick embryo culture process. The recombinant virus fully meets the biological safety requirements and has a good application prospect.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: November 29, 2022
    Assignee: SOUTH CHINA AGRICULTURAL UNIVERSITY
    Inventors: Wenbao Qi, Ming Liao, Yiqun Chen, Jiahao Zhang, Bo Li, Jinyu Huang, Huanan Li
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • Method for virus assay
    Patent number: 11513121
    Abstract: The present invention relates to a method for virus assay. More closely the invention relates a method for total quantification of adenovirus in a sample as well as total and functional (active) adenovirus in a sample. The method for determining adenovirus concentration in a sample comprises subjecting said sample to SPR (surface plasmon resonance) assay with immobilized FX (Factor X) and/or immobilized CAR (coxsackievirus and adenovirus receptor) on a sensor surface, wherein the adenovirus concentration is determined from sample binding to immobilized FX and/or immobilized CAR. CAR can be replaced by an ligand binding to adenovirus fiber, such as an anti-adenovirus fiber antibody. FX can be replaced by a ligand binding to adenovirus hexon, such as an anti-adenovirus hexon antibody. The method can be used for quality control in an adenovirus purification process, for example for gene therapy.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 29, 2022
    Assignee: CYTIVA SWEDEN AB
    Inventors: Asa Frostell, Elisabeth Wallby, Asa Hagner-McWhirter, Linnea Nygren Babol
  • Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
    Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • Adeno-associated virus (AAV) with modified phospholipase domain
    Patent number: 11499141
    Abstract: The present disclosure relates generally to modified adeno-associated virus (AAV) from serotypes other than serotype 2, which have a viral capsid protein with a subunit 1 (VP1) sequence which is modified relative to the corresponding wildtype sequence. In particular, the modified AAVs of the disclosure comprise site-specific amino acid substitutions within the phospholipase A2 (PLA2) domain and flanking sequence relative to the corresponding wild-type sequence which improve functionality of the AAV when produced in insect cells. The present disclosure also relates to methods of producing the modified AAVs, reagents therefor, baculovirus expression systems and insect cells for producing said modified AAVs.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 15, 2022
    Assignee: Benitec IP Holdings Inc.
    Inventors: Vanessa Strings-Ufombah, Shih-Chu Kao, Petrus W. Roelvink
  • Parvovirus structural protein for the treatment of autoimmune diseases
    Patent number: 11492377
    Abstract: The present invention relates to a mutated parvovirus structural protein, comprising at least one insertion comprising a sequence of at least six consecutive amino acids comprised within amino acids 320 to 641 of human HSP70i. Furthermore, the invention relates to multimeric structures comprising the protein, VLPs, a method of producing the mutated parvovirus structural protein and to medicaments or vaccines comprising the mutated parvovirus structural protein that may be used for treating vitiligo or other autoimmune diseases.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: November 8, 2022
    Assignee: 2A PHARMA AB
    Inventor: Jeanette Prangsgaard
  • Method for inactivating Zika virus and for determining the completeness of inactivation
    Patent number: 11478541
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford
  • Coronavirus disease (COVID-19) vaccine
    Patent number: 11478543
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 25, 2022
    Assignee: Thomas Jefferson University
    Inventors: Matthias J. Schnell, Christoph Wirblich, Drishya Kurup
  • Genetic construct
    Patent number: 11471539
    Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for treating a range of disorders, including glaucoma and deafness, or for promoting nerve regeneration and/or survival.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: October 18, 2022
    Assignee: QUETHERA LIMITED
    Inventors: Peter Widdowson, Keith Martin
  • Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection
    Patent number: 11471523
    Abstract: The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes. The universal vaccines are prepared against an immunogen of an infectious pathogenic organism selected from a virus, a bacteria, a fungus or a protozoan comprising at least one ribonucleic acid (RNA) polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in CD8+ T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in a humanized mouse model comprising a fully functional human immune system.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: October 18, 2022
    Assignee: CN.USA BIOTECH HOLDINGS, INC.
    Inventors: Jian Qing Xu, Xiao Yan Zhang, Jing Wang, Ling Yan Zhu, Beverly W. Lubit
  • Hybrid alphavirus-SARS-CoV-2 particle and methodology of making and using same
    Patent number: 11473064
    Abstract: Timely development of vaccines and antiviral drugs is critical to control the COVID-19 pandemic. Current methods for quantifying vaccine-induced neutralizing antibodies involve the use of pseudoviruses, such as the SARS-CoV-2 spike protein (S) pseudotyped lentivirus. However, these pseudoviruses contain structural proteins foreign to SARS-CoV-2, and require days to infect and express reporter genes. Here, the present application discloses composition and methodology for making and using a new hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) particle for rapid and accurate quantification of neutralization antibodies and viral variants.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: October 18, 2022
    Assignee: George Mason Research Foundation, Inc.
    Inventors: Brian Hetrick, Yuntao Wu
  • AAV capsids identified by in vivo library selection
    Patent number: 11472848
    Abstract: The disclosure relates, in some aspects, to adeno-associated vims capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 18, 2022
    Assignees: University of Massachusetts, The Johns Hopkins University, Kennedy Krieger Institute, Inc.
    Inventors: Miguel Sena Esteves, Sourav Roy Choudhury, Kathryn Rae Wagner, Jennifer Gifford Green, Ana Rita Batista
  • Virus-like nanoparticles for oral delivery
    Patent number: 11466055
    Abstract: A Hepatitis E virus (HEV)-based virus like nanoparticle (HEVNP) made with a modified capsid protein containing at least a portion of open reading frame 2 (ORF2) protein conjugated with gold nanocluster is provided. Also provided are methods of targeted delivery of a nucleic acid using the HEVNP.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 11, 2022
    Assignee: The Regents of the University of California
    Inventors: R. Holland Cheng, Chun Chieh Chen, Mohammad Ali Baikoghli, Marie Stark
  • RNA-based delivery systems with levels of control
    Patent number: 11453893
    Abstract: Disclosed herein include methods, compositions, and systems suitable for use in delivering a polynucleotide to a target cell of a subject in need thereof. In some embodiments, a viral vector comprises a polynucleotide encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), RNA-dependent RNA polymerase (L), and one or more transgenes. The viral vector can comprise one or more of a conditionally stable fusion protein, a protease fusion protein, a degron fusion protein, and/or a glycoprotein derived of another species than the viral vector polynucleotide to enable control of viral vector transduction and/or replication.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: September 27, 2022
    Assignee: California Institute of Technology
    Inventors: Xiaojing Gao, Lucy S. Chong, Michael B. Elowitz, Matthew S-M Kim
  • Immunostimulatory compositions
    Patent number: 11447779
    Abstract: The present disclosure relates to immunostimulatory compositions that are effective in eliciting immune responses in avian species. More specifically, these immunostimulatory compositions comprise an immunomodulator composition and an immunostimulatory oligonucleotide that when administered stimulate toll-like receptor 21.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: September 20, 2022
    Assignee: Bayer Animal Health GmbH
    Inventor: Thomas Ilg
  • Influenza virus vaccines and uses thereof
    Patent number: 11447526
    Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 20, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina Jongeneelen, Daphné Truan, Johannes Petrus Maria Langedijk